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lator of T cell activation, differentiation, and function
(Dong et al., 2001; McAdam et al., 2001; Nurieva et al.,
2003; Tafuri et al., 2001). PD-1, another ITIM-containingSummary
receptor expressed on activated T cells, binds to B7-
H1/PDL1 and PDL2/B7DC that are broadly expressedT cell activation by antigen-presenting cells (APC) is
regulated by positive and negative costimulatory mole- in APC and nonlymphoid tissues (Dong et al., 1999;
Freeman et al., 2000; Latchman et al., 2001; Tseng etcules in the B7 family. Here we describe a novel addition
in this family, designated as B7S1, which is uniquely al., 2001). PD-1 plays an important role in maintaining
immune tolerance as PD-1-deficient mice develop multi-anchored to the cell membrane via a GPI linkage. B7S1
is expressed on professional APC and widely distrib- ple autoimmune diseases on different genetic back-
grounds (Nishimura et al., 1999, 2001). B7-H3 is theuted in nonlymphoid tissues. A soluble B7S1-Ig fusion
protein binds to activated but not naive T cells. B7S1- newest addition to the B7 family whose receptor has
not been identified (Chapoval et al., 2001; Sun et al.,Ig inhibits T cell activation and IL-2 production. A
monoclonal antibody that blocks binding of B7S1 to 2002). B7-H3 was first reported to be expressed by hu-
man dendritic cells and to stimulate human T cell pro-its receptor enhances T cell proliferation in vitro and
exacerbates experimental autoimmune encephalomy- liferation and IFN production (Chapoval et al., 2001).
Recently, we identified the mouse B7-H3 homolog thatelitis in vivo. This study identifies a novel negative
regulator of T cell activation and further reveals com- is broadly expressed in lymphoid and nonlymphoid tis-
sues; a soluble mouse B7-H3-Ig fusion protein binds toplex costimulatory regulation of immune responses.
activated but not naive T cells (Sun et al., 2002). There-
fore, the new members of the B7 family are broadlyIntroduction
expressed on professional APC and in nonlymphoid tis-
sues, and through their receptors on activated T cellsT cell activation requires two signals: one via TCR recog-
nition of antigenic peptides presented by MHC mole- regulate T cell activation and effector function.
Here we describe a novel member of the B7 familycules and the other from costimulatory molecules on
the antigen-presenting cells (APC) (Mueller et al., 1989). named as B7 superfamily member 1 (B7S1). B7S1 is
expressed on professional APC and is broadly distrib-The best-characterized costimulatory molecules are
CD80 and CD86, also known as B7.1 and B7.2, respec- uted in nonlymphoid tissues. Its expression on B cells
is downregulated following their activation. Unlike thetively, which are expressed by professional APC as a
result of innate activation (Janeway and Medzhitov, other known members of the B7 family, B7S1 is an-
chored to the cell membrane via a glycosyl phosphati-2002). The receptors for CD80 and CD86 are CD28 and
CTLA4. CD28 is expressed by naive and activated dylinositol (GPI) linkage. A soluble B7S1-Ig protein binds
to activated but not naive T cells. B7S1-Ig reduces T cellT cells, and plays a major role in T cell activation. Mice
lacking CD28 or both CD80 and CD86 are impaired in proliferation by inhibiting IL-2 production. An anti-B7S1
blocking antibody enhances T cell proliferation and IL-2T cell immune responses in vitro and in vivo (Lenschow
et al., 1996). CTLA4, on the other hand, is induced after secretion in vitro. In vivo blockade of B7S1 also led to
greater T-dependent immune responses and exacerba-T cell activation and binds to the same ligands with
a higher affinity (Chambers and Allison, 1999). CTLA4 tion of experimental autoimmune encephalomyelitis
(EAE). Therefore, B7S1 is a novel negative costimulatorcarries an ITIM motif in its cytoplasmic region and func-
tions as a negative regulator of T cell activation; CTLA4 and regulates the threshold of T cell activation.
knockout mice develop profound autoimmune diseases
(Thompson and Allison, 1997). Therefore, CD28 and Results
CTLA4 engaged by CD80 and CD86 molecules on APC
play essential roles in maintaining the threshold of T cell Identification of B7S1 as a New Member
activation. of the B7 Family
In the past several years, the B7 ligand and the corre- To identify novel members of the B7 family with potential
sponding CD28 receptor families have been vastly ex- function in immune regulation, we performed a homol-
panded. Inducible costimulator (ICOS), a third member ogy search in mouse and human EST databases using
of the CD28 family, is expressed on activated but not amino acid sequences of B7h and B7-H3. Human
naive T cells, and recognizes its own ligand B7h (also FLJ22418 molecule was found to share significant ho-
named as B7RP-1 etc) (Hutloff et al., 1999; Yoshinaga mology with these two B7-like molecules (data not
et al., 1999). B7h is constitutively expressed in certain shown). In addition, a mouse EST clone was found to
contain nucleotide sequence encoding amino acids that
are similar to the most N terminus of FLJ22418. We*Correspondence: chendong@u.washington.edu
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Figure 1. Identification of B7S1 as a Novel Member of the B7 Superfamily
(A) Nucleotide sequence of B7S1 cDNA encompassing the open reading frame.
(B) Alignment of deduced amino acid sequence of mouse B7S1 cDNA with its human homologs. The N-terminal leader peptide and C-terminal
hydrophobic regions are indicated by straight lines; Ig-like domains, by dotted lines. The residues conserved in all members of the B7 family
are indicated by underlines.
(C) Phylogenic analysis of the B7 family members. The scores at each branch represent the degree of sequence variability between proteins
(0 for identical sequences). Percentage of amino acid identity between B7S1 protein and the other members of the B7 family is indicated.
obtained this clone and completely sequenced it (Figure We constructed a mouse B7S1-Ig fusion protein as
we previously reported for mouse B7-H3 (Sun et al.,1A). The deduced peptide sequence from the mouse
open reading frame shares striking homology with the 2002). In brief, the nucleotide sequence encoding the
extracellular portion of the mouse B7S1 molecule (aminohuman protein (Figure 1B). They all contain an N-terminal
hydrophobic region that can serve as a leader peptide, acids 31-254) was amplified and cloned into the DES-
Ig insect expression vector. This new plasmid was stablytwo immunoglobulin (Ig)-like domains, and a hydropho-
bic C terminus (Figure 1B). Therefore, this novel protein transfected into the S2 Drosophila cells that can be
induced to secrete large amounts of B7S1-Ig fusion pro-shares common structural features with known mem-
bers of the B7 family. In a phylogenic analysis, we found teins. B7S1-Ig protein produced in this fashion was then
purified by a Protein A column.it to be similar to all existing B7 family members with
20%–30% amino acid identity (Figure 1C). It is notewor- We used B7S1-Ig fusion protein to immunize a female
Lewis rat as described in the Experimental Proceduresthy that this degree of homology is also observed among
other B7 molecules and even between B7.1 and B7.2 section. The harvested draining lymph node cells were
fused with Ag8.653. After selection, hybridoma clonesthat share the same receptors (Carreno and Collins,
2002). However, all critical cysteine residues as well were screened by ELISA for production of antibodies
that react against B7S1-Ig but not to human IgG1. Threeas the DxGxYxC motif in the first Ig-like domain are
conserved in these proteins (Figure 1B). We also com- IgG monoclonal antibodies were generated by this
means, which also stained 293 cells transiently trans-pared the amino acid sequence of B7S1 with those in
the CD28 family—CD28, ICOS, and PD-1, which also fected with a mouse B7S1 expression vector but not to
the mock transfectant (Figure 2A; data not shown). Wepossess extracellular Ig-like domains, and found no sig-
nificant homology (data not shown). Therefore this mole- have characterized two of them, the clone 9 and 54
antibodies, in more detail and found they did not bindcule is a novel member of the B7 family and we name
it B7 superfamily member 1 (B7S1). to 293 cells transfected with a B7-H3 expression plasmid
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Figure 2. B7S1 Anchors to the Cell Membrane via a GPI Linkage
(A) Generation of monoclonal antibodies to mouse B7S1. Supernatants from anti-B7S1 hybridoma clones 9 and 54 were used to stain B7S1-,
mock-, or B7-H3-transfected 293 cells, and the staining was revealed by an anti-rat IgG-FITC.
(B) B7S1 expression is sensitive to PI-PLC treatment. 293 cells transfected with a B7S1 expression vector (for B7S1) or EL-4 cells (for Thy1
and ICOS) were treated with PI-PLC at 37C for 30 min. Cells with (PI-PLC) or without the treatment (NT) were stained with antibodies to
these antigens. Mean fluorescence (MF) of each staining is indicated.
(Figure 2A). In addition, PDL2-Ig did not block the bind- Expression of B7S1 Molecule by Professional APC
All known members of the B7 family are expressed bying of these antibodies (data not shown). These results
professional APC. In addition, the new members of thisindicate that we have generated B7S1-specific anti-
family, i.e., B7h, PDL1, PDL2, and B7-H3 are broadlybodies.
distributed in nonlymphoid tissues and cells. To assessAlthough the C terminus of B7S1 protein is hydropho-
the possible immune regulation by B7S1, we first exam-bic, it is not followed by any residues that can be pre-
ined the expression of B7S1 mRNA by a Northern blotdicted as intracellular amino acids. This structural char-
analysis. A cDNA probe consisting of the coding se-acteristic is usually shared by cell surface GPI-anchored
quence for the extracellular region of B7S1 is utilized.proteins (Udenfriend and Kodukula, 1995). We therefore
B7S1 expression can be detected in lymphoid tissuestested whether cell surface expression of B7S1 is sensi-
thymus and spleen, and in a number of nonlymphoidtive to phosphatidylinositol-specific phospholipase C
organs (Figure 3A). Ubiquitous expression of B7S1 in(PI-PLC) treatment. Indeed, PI-PLC reaction resulted
nonlymphoid tissues suggests its role in modulating im-in 50% reduction of B7S1 expression on transfected
mune responses in these tissues. In most tissues, two
293 cells (Figure 2B). Similarly, expression of native mRNA species were detected, but the nature of this size
B7S1 protein on splenic B cells (see below) was also difference is unclear at this stage.
sensitive to the treatment of PI-PLC (data not shown). We then further examined B7S1 expression in immune
As a positive control, expression of GPI-anchored Thy1 cells by use of the anti-B7S1 monoclonal antibody. In
molecule on EL-4 cell line can be reduced to a similar thymus, B7S1 is expressed by a minor population of
extent by PI-PLC while transmembrane protein ICOS is cells that also express CD4 and CD8 (Figure 3B). In
largely insensitive (Figure 2B). B7S1 thus represents the spleen, B7S1 is not expressed by CD4, CD8, or
first GPI-linked protein in the B7 family although the CD11C cells, but is constitutively on all B220 B cells
functional significance of this configuration is unknown (Figure 3B). Therefore in secondary lymphoid organs,
B7S1 appears to exhibit B cell-specific expression.at this stage.
Immunity
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Figure 3. Expression of B7S1 in Tissues and by Immune Cells
(A) A PCR fragment consisting of two Ig-like domains of the mouse B7S1 gene was used to hybridize mouse tissue Northern blot (Seegene,
Inc., Korea).
(B) Expression of B7S1 by thymocytes, spleen cells, and peritoneal macrophages. Cells were stained with a biotinylated anti-B7S1 antibody
in conjunction with other indicated markers.
However, B7S1 expression can be detected on perito- activation (Janeway and Medzhitov, 2002; Lenschow
et al., 1996); B7h is downregulated on B cells by IgMneal CD11b macrophages elicited by thioglycollate
(Figure 3B) and on some bone marrow-derived CD11C engagement and upregulated on fibroblasts by TNF
(Liang et al., 2002; Swallow et al., 1999). We thereforedendritic cells (data not shown). This analysis indicates
that B7S1 is expressed by a variety of professional APC examined whether B7S1 is regulated in APC. LPS treat-
ment of peritoneal macrophages or bone marrow-and may possess regulatory roles on T cells.
Members of the B7 family are differentially regulated derived dendritic cells did not significantly alter the B7S1
expression (data not shown). On the other hand, stimula-in professional APC by various stimuli. For instance,
CD80 and CD86 expression can be induced by innate tion of purified splenic B cells by different stimuli, includ-
B7S1, an Inhibitor of T Cell Activation
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Figure 4. B7S1-Ig Binds to Activated T Cells
Lymph node cells from a C57BL/6 mouse
were activated with ConA for 48 hr, and cells
before and after activation were analyzed for
B7S1-Ig binding together with antibodies for
CD4 and CD8.
ing LPS, IL-4, anti-IgM, and anti-CD40, all resulted in rived from our insect culture system, we employed an
irrelevant protein containing the human IgG1 tag ex-50%–70% reduction of B7S1 expression: LPS reduced
pressed and prepared in the same fashion as B7S1-IgB7S1 expression by 54%, IL-4 by 60%, and anti-IgM or
and found it had no effect on T cell proliferation (dataanti-CD40 by 71%. This result indicates that B7S1 is
not shown). B7S1-Ig inhibited proliferation of OT-IIdownregulated after B cell activation.
transgenic T cells in a dose-dependent manner (Figure
5C). B7S1-Ig treatment also moderately reduced CD25Inhibition of T Cell Activation by B7S1-Ig
and CD44 upregulation on activated OT-II T cells (dataExpression of B7S1 on professional APC suggests a
not shown). In the presence of CD28 costimulation,role of B7S1 in regulation of T cell immune responses.
B7S1-Ig inhibited T cell proliferation, most potentlyWe employed our B7S1-Ig fusion protein to assess if
when low dose of anti-CD3 was used (Figure 5D). Inter-B7S1 has a putative receptor on T cells. CD4 and CD8
estingly, strong TCR and CD28 costimulation can par-
T cells from C57BL/6 lymph nodes are not strongly
tially overcome this inhibition (Figure 5D). These results
bound by the biotinylated B7S1-Ig; after ConA activation
indicate B7S1 as a negative regulator of T cell activation
for 2 days, all of them do (Figure 4). B7S1-Ig bound to
and B7S1-Ig treatment render the cells less responsive
CD28/ cells in the same degree (data not shown). to TCR and CD28 signaling.
B7.1-Ig did not block binding of B7S1-Ig to activated The hallmark of T cell activation is the production
T cells (data not shown), suggesting that it does not of IL-2, which drives T cell clonal expansion. We thus
recognize CD28 or CTLA4. In addition, B7S1-Ig could examined whether IL-2 production is affected by B7S1-
bind well to ICOS/ cells activated by ConA (data not Ig costimulation. While B7.1-Ig strongly potentiated IL-2
shown). It does not stain 293 cells transfected with PD-1, production, B7S1-Ig inhibited (Figure 5E). B7S1-Ig also
which could be recognized by an anti-PD-1 antibody inhibited IL-2 production by cells treated with anti-CD3
(data not shown). B7-H3-Ig and B7S1-Ig did not recipro- and anti-CD28 (data not shown). To assess whether
cally block the binding of the other fusion protein to inhibition of T cell proliferation by B7S1-Ig was the result
their corresponding receptor on activated T cells (data of IL-2 reduction, we added exogenous IL-2 to the OT-II
not shown). All these data indicate a putative receptor T cells treated with anti-CD3 with or without B7S1-Ig.
for B7S1 on activated T cells, which is distinct from Addition of IL-2 fully restored the proliferation of T cells
CD28, CTLA4, ICOS, PD-1, and the receptor for B7-H3. costimulated with B7S1-Ig (Figure 5F). Therefore, B7S1
To assess the function of B7S1 on T cell activation inhibits T cell activation via reducing the IL-2 production.
and function, we stimulated purified CD4 cells from Effector Th cells differentiated in this fashion exhibited
C57BL/6 (Figure 5A) or OT-II TCR transgenic (Figure 5B) no cytokine defect (data not shown). Our work suggests
mice with different doses of anti-CD3 in the absence that B7S1 primarily inhibits T cell activation and IL-2
or presence of B7.1-Ig or B7S1-Ig and measured cell production.
proliferation. Anti-CD3 plus a human IgG1 control re- IL-2 gene induction in activated T cells is the result of
sulted in the similar proliferation of stimulated T cells multiple signaling pathways from cell surface receptors
as the ones treated with anti-CD3 only (data not shown). leading to activation of NFAT, NF-B, and AP1 transcrip-
B7.1-Ig, as expected, strongly enhanced T cell stimula- tion factors (Jain et al., 1995; Serfling et al., 1995). We
tion (Figure 5A). B7S1-Ig on the other hand inhibited assess whether B7S1-Ig costimulation resulted in an
T cell proliferation (Figures 5A and 5B). To rule out the inhibition of IL-2 transcription machinery. OT-II T cells
were treated with anti-CD3 in the presence or absencepossibility that this inhibitory effect was artificially de-
Immunity
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Figure 5. B7S1-Ig Inhibits T Cell Proliferation and IL-2 Production
(A–C) CD4 T cells isolated from C57BL/6 (A) or OT-II (B and C) mice were treated with indicated doses of various stimuli, and T cell proliferation
measured by 3H-thymidine incorporation.
(D) CD4 T cells from C57BL/6 mice were stimulated with indicated doses of anti-CD3 with or without anti-CD28 (2 g/ml) in the presence or
absence of B7S1-Ig and their proliferation measured.
(E) OT-II T cells were treated by indicated means for 24 hr and IL-2 expression measured by ELISA.
(F) Exogenous IL-2 restored proliferation by B7S1-treated OT-II cells. OT-II cells were treated as in (B) at the presence of exogenous IL-2 (30
units/ml) and cell proliferation assayed.
of B7S1-Ig costimulation and nuclear extracts prepared of which is unknown, B7S1 costimulation may result in
inefficient JunB induction. Overall, this analysis sug-16 hr after stimulation. Nuclear localization of NFATc1
and c-rel transcription factors, both of which bind to the gests B7S1-Ig treatment may lead to a selective signal-
ing and transcription defect.IL-2 promoter and are important for its induction, is the
result of T cell activation (Kontgen et al., 1995; Peng et
al., 2001; Zhou et al., 2002). B7S1-Ig costimulation did Enhanced T Cell Activation by an Anti-B7S1
Blocking Antibodynot reduce the amount of these two factors in the nu-
cleus as examined by Western blotting (data not shown). To assess the physiological importance of B7S1 binding
to its corresponding receptor in immune responses, weHowever, the expression of JunB, a component of the
AP-1 family induced after T cell activation, was reduced employed an anti-B7S1 blocking antibody for our in vitro
and in vivo analysis. We found that clone 54 antibodyby 49% after B7S1 costimulation. On the other hand,
there was little change in c-Jun expression (11% reduc- inhibited binding of B7S1-Ig to activated T cells (Figure
6A), while clone 9 did not significantly (data not shown).tion) with B7S1-Ig treatment. JunB has been previously
shown to bind to the IL-2 promoter (Boise et al., 1993) We first assessed the function of this blocking anti-
body in vitro by activating splenocytes from C57BL/6and JunB overexpression resulted in greater IL-2 pro-
duction (our unpublished data). Since JunB is induced mice with different doses of anti-CD3. In this experiment,
positive and negative costimulation is provided by dif-after T cell activation (Jain et al., 1995), the mechanism
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T cells (Figure 6C). This work substantiates the above
data using B7S1-Ig and indicates that B7S1 is a physio-
logical negative regulator of T cell activation and IL-2
expression.
To examine if negative regulation by B7S1 has any
important immune function in vivo, we immunized
C57BL/6 mice at their base of tail with KLH protein
emulsified in CFA. A control rat IgG or the B7S1 blocking
antibody was injected into experimental mice every
other day for a total of 3 times. 8 days after the immuniza-
tion, the mice were sacrificed and anti-KLH antibody in
the serum was measured. We found that treatment with
anti-B7S1 blocking antibody led to greater anti-KLH IgM
(Figure 7A) and IgG (data not shown) production, indica-
tive of a stronger immune responses in vivo. We also
collected spleen cells from immunized mice and restim-
ulated them in vitro with or without 10 g/ml KLH. Cells
from anti-B7S1 treated mice consistently exhibited
greater proliferation and IL-2 production (Figures 7B
and 7C), also suggesting that stronger T cell priming
occurred in vivo in the presence of anti-B7S1 blocking
antibody.
To assess the importance of B7S1 in T cell activation
and tolerance, we immunized C57BL/6 with MOG35-55
peptide as we described before to induce EAE disease
(Dong et al., 2001). Control or anti-B7S1 blocking anti-
body was injected into mice during T cell priming phase,
i.e., between first and second immunization. Mice
treated with anti-B7S1 blocking antibody consistently
developed greatly accelerated and much more robust
EAE than those treated with a control rat antibody (Fig-
ure 7D). When we examined infiltrating mononuclear
cells in the brain of experimental mice, we found that
anti-B7S1 antibody treatment in mice resulted in greater
CD4 and CD8 cell infiltration, and also remarkably in-
creased CD11b macrophages (Figure 7E). This work
strongly supports an essential function of B7S1 in nega-
tive regulation of T cell activation.
Discussion
T cell activation requires two signals: one from TCR and
the other from costimulatory molecules, most notably
those in the B7 family. Recent expansion of the B7 family
has revealed complex costimulatory regulation of T cell
activation (Frauwirth and Thompson, 2002; Carreno and
Collins, 2002; Sharpe and Freeman, 2002). The new
Figure 6. Anti-B7S1 Blocking Antibody Enhanced T Cell Prolifera- members of the B7 family are more broadly expressed,
tion and IL-2 Production In Vitro bind to receptors on activated T cells, and exert positive
(A) Biotinylated B7S1-Ig was incubated with a rat control Ig (no and negative regulation of T cell activation program.
blocking) or clone 54 anti-B7S1 (blocking) before staining with
Here we describe for the first time one such molecule—ConA-activated mouse lymph nodes cells.
B7S1. We show that it functions as a negative regulator(B and C) Spleen cells from C57BL/6 mice were incubated with
of T cell activation and IL-2 production.indicated doses of anti-CD3 at the presence of 5 g/ml control rat
IgG or purified clone 54 antibody. Cell proliferation (B) was measured B7S1, like other B7 family members, possesses one
by 3H-thymidine uptake after 72 hr and IL-2 (C) assayed by ELISA pair of Ig-like domains in its extracellular region (Figure
24 hr after the treatment. 1B). However, it lacks an obvious transmembrane re-
gion. We showed that its cell surface expression is sensi-
tive to PI-PLC treatment (Figure 2B) and concluded thatferent splenic APCs, mostly B cells. While a control rat
IgG did not alter T cell proliferation, treatment with anti- B7S1 is anchored to the cell membrane via a GPI linkage.
Thus B7S1 is the first GPI-linked protein in the B7 family,B7S1 blocking antibody greatly enhanced it (Figure 6B).
We also measured IL-2 production within the first 24 hr and the rest are type I transmembrane glycoproteins.
The functional significance for the unique cell membraneof treatment, and found that B7S1 blocking antibody
also greatly increased the levels of IL-2 production by anchorage of B7S1 is unclear. Although originally thought
Immunity
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Figure 7. Anti-B7S1 Blocking Antibody Enhanced T-Dependent Immune Responses and EAE Disease In Vivo
(A–C) C57BL/6 mice (three in each group) immunized with KLH in CFA were treated with a rat control Ig or anti-B7S1 blocking antibody. Eight
days after the immunization, experimental mice were sacrificed and anti-KLH serum IgM was measured individually by ELISA and averaged
for each group (A). Spleen cells from each immunized mouse were restimulated in vitro with or without KLH and T cell proliferation (B) and
IL-2 production (C) was measured an average for the control antibody or anti-B7S1 groups is indicated.
(D and E) C57BL/6 mice (five mice in each group) immunized with MOG peptide to induced EAE were treated with a rat control Ig or anti-
B7S1 blocking antibody. (D) EAE disease in these mice was scored as described in the Experimental Procedures. The result shown is a
representative of two independent experiments with similar results.
(E) Mononuclear cells in CNS from mice with EAE were typed by staining with anti-CD4, CD8, or CD11b.
to be more mobile on cell membrane than transmem- B7S1 is influenced by the activation status of B cells. It is
noteworthy that other B7 family members are regulatedbrane proteins, GPI-linked proteins are preferentially lo-
calized in the lipid rafts. Lipid rafts on T cells are thought differentially in B cells. CD80 and CD86 are well known
to be upregulated after B cell activation while B7h isto play important roles in the organization of immunolog-
ical synapses. However, its role in APC has not been downregulated only after IgM crosslinking (Liang et al.,
2002). All these suggest a combinatorial model for co-well established. Recently, MHC class II molecules have
been shown to be localized in lipid rafts, which allows stimulation of T cells: each B7 ligand is regulated differ-
entially, which reflects the natural history and activationefficient antigen presentation (Anderson et al., 2000).
With a GPI linkage, B7S1 may be in close proximity to states of APC, and the combination of these ligands
regulate the threshold of T cell activation. On the otherthe MHC and this spatial organization may allow efficient
negative costimulation to occur. hand, the new B7 family members- B7h, PDL1/2, B7-
H3, and B7S1 are also widely distributed in nonlymphoidWith the monoclonal antibodies we generated against
mouse B7S1 molecule, we found B7S1 is expressed by tissues. Since their receptors are expressed on acti-
vated T cells, they may possess important function inmost professional APC, including some bone marrow-
derived dendritic cells, all peritoneal macrophages and modulating effector T cell function once activated T cells
migrate into the nonlymphoid tissues. It is also possiblesplenic B cells (Figure 3B). Its expression on B cells can
be downregulated by different stimulation. This obser- that at this effector stage, the combinatorial signals pre-
sented by B7 ligands that are tissue-specific and regu-vation suggests costimulatory regulation of T cells by
B7S1, an Inhibitor of T Cell Activation
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lated by inflammatory cytokines may influence the na- B7S1 antibody (Figure 7E). Macrophages were also
ture and extent of T cell function. greatly increased in number in these mice as well. These
A B7S1-Ig fusion protein we prepared bound to acti- results indicate an essential regulation of B7S1 in nega-
vated but not naive CD4 and CD8 cells. Therefore, tive regulation of T cell-dependent autoimmune reac-
B7S1 joins B7h, PDL1/2, and B7-H3 to recognize recep- tion. From all data presented in this paper, the primary
tors induced after T cell activation. The nature of the cause of this greatly enhanced autoimmunity may be
B7S1 receptor is unknown at this stage, but appears primarily due to excessive T cell activation and clonal
distinct from known members of the CD28 receptor fam- expansion in vivo. However, we cannot rule out that
ily. B7S1-Ig can bind to CD28/ and ICOS/ cells; this B7S1 may be additionally important to inhibit certain
binding is not inhibited by a B7.1-Ig or B7-H3-Ig. In effector or to generate regulatory T cells in vivo that
addition, it does not react with a PD-1 transfectant. The function to contain autoimmunity, although we do not
CD28 family is thus expected to expand in the near have any supporting evidence from our current work
future. Also with the fusion protein, we tested the func- along this line. Nonetheless, the EAE experiment
tion of B7S1 on T cell activation and differentiation. strongly suggests that B7S1 contributes in certain de-
B7S1-Ig very potently inhibited CD4 T cell proliferation grees to the maintenance of peripheral tolerance and
(Figures 5A–5D). We further showed that B7S1 reduction to the containment of autoimmune diseases.
of T cell proliferation is through an IL-2-dependent Overall, we identify a novel member of the B7 family
mechanism. B7S1-Ig greatly reduced the IL-2 produc- that serves as a negative regulator of T cell proliferation
tion by activated T cells and addition of exogenous IL-2 and IL-2 production. B7S1 is downregulated after B cell
restored the proliferation of T cells by B7S1-Ig-treated activation, which may result in lowering the T cell activa-
cells (Figures 5E and 5F). These data demonstrated that tion threshold. Therefore this study further demonstrates
B7S1 can serve as a negative regulator of T cell activa- complex regulation of T cell activation via positive and
tion and IL-2 production. How B7S1 works is unclear at negative costimulatory molecules as suggested by others
this stage, but we found that JunB induction in activated (Frauwirth and Thompson, 2002; Carreno and Collins,
T cells is most significantly reduced when T cells are 2002; Dong et al., 2002; Sharpe and Freeman, 2002).
costimulated by B7S1. JunB is induced after T cell acti- Therapeutic intervention of these costimulatory path-
vation and functions to regulate IL-2 gene transcription. ways may help modulate immune responses in many
It is interesting that B7S1 at this stage does not globally diseases.
inhibit all signaling pathways but instead selectively
Experimental Proceduresblocks a specific mechanism. Further analysis of B7S1
signal transduction will therefore reveal more complex
B7S1 Cloning and Analysissignaling mechanisms of costimulatory molecules.
Mouse B7S1 EST clone was purchased from Incyte and completelyWe have examined the physiological significance of
sequenced. The Ig-like domains of the deduced B7S1 protein were
B7S1 costimulation by use of a blocking antibody. Treat- predicted by CD-Search program of NCBI. The alignment of mouse
ment of anti-CD3-activated splenocytes with this anti- and human B7S1 protein sequences was performed using Jellyfish
body greatly enhanced IL-2 production and T cell prolif- software, Biowire. The phylogeny tree was constructed with Gene-
Works software. Comparison of amino acid sequences of B7S1 witheration (Figures 6B and 6C). This work, in agreement
other B7 family members was performed using the blast2 programwith our results using B7S1-Ig (Figures 5A–5F), indicates
of NCBI and DS Gene 1.1. Mouse tissue Northern blot was pur-that B7S1 expressed on APC does function physiologi-
chased from Seegene, Inc., Seoul, Korea. A PCR fragment con-cally to limit the amount of IL-2 expression by activated
sisting of two Ig-like domains of the mouse B7S1 gene, which was
T cells and hence the extent of their clonal expansion. subsequently cloned into the insect expression vector (see below),
More importantly, blocking of B7S1 function led to was used for the analysis. The final wash of the blot was performed
greater T cell priming and function in vivo. In an immuni- with 0.1	 SSC/0.1% SDS at 65C.
zation experiment, we found that treatment of immu-
B7S1 Expressionnized mice with anti-B7S1 blocking antibody led to
The sequence coding the extracellular portion of the protein wasgreater antigen-specific Ig production (Figure 7A). Fur-
PCR amplified and cloned into the DES-Ig plasmid we previouslythermore, enhanced IL-2 production and T cell prolifera- described (Sun et al., 2002). The PCR primers, with restriction sites,
tion by restimulated spleen cells harvested from anti- were: forward, AGATCTATTTCAGGCAAGCACTTCATCAC, and re-
B7S1 treated mice also support that T cell priming was verse, ACTAGTGAGCAGCTGCAGCTGACTCCGCC. The new B7S1-
indeed enhanced in vivo (Figures 7B and 7C). Thus Ig expression vector was stably transfected into Drosophila S2 cells
which upon CuSO4 induction, secrete B7S1-Ig fusion protein. Theblocking B7S1 may possess potential therapeutic values
B7S1-Ig fusion protein produced by this fashion was further purifiedin enhancing wanted immune responses.
by a Protein A column. B7S1, B7-H3 and PD-1 expression vectorsWe further assess the importance of B7S1 negative
were transfected into 293 cells by Lipofectamin 2000, Clontech.
costimulation using an autoimmunity mouse model—
MOG-induced EAE in C57BL/6 mice. Anti-B7S1 blocking Generation of Anti-B7S1 Monoclonal Antibodies
antibody treatment led to an extreme EAE disease. It is A female Lewis rat (3–4 months old) was immunized with 100 g
noteworthy that the antibody was injected into experi- B7S1-Ig in complete Freund’s adjuvant (CFA) at the foodpad, axial,
and linguinal areas and boosted every 3rd day 5 times in the samemental mice at T cell priming phase, i.e., after the first
protein quantity with antigen in IFA. The draining lymph node cellsimmunization but before the second. The disease nor-
were harvested 1 day after the last boost and fused with Ag8.653mally becomes observable only after the second immu-
cells by PEG1500 as previously described (Kubagawa et al., 1999).
nization. Therefore, anti-B7S1 effect may be due to the ELISA was performed to identify the clones that produced IgG anti-
enhanced expansion of autoreactive T cells. In support bodies reacting with B7S1-Ig fusion protein but not with control
of this idea, we did find greater CD4 and CD8 T cell human IgG1. These clones were further subcloned and a total of 3
clones were generated.infiltration into the brain tissue in mice treated with anti-
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